News
Find out all the latest news and information on DHDDS here
Charlie Dixon’s cycle to raise funds for Cure DHDDS features in the ITV news
Cure DHDDS Win Award for Excellence in Medical Affairs-Led Scientific Exchange
DHDDS Founder Speaks at ORPHAN DRUGS & RARE DISEASES GLOBAL CONGRESS 2024
Cure DHDDS in the Press!
Founders of Cure DHDDS USA Share interviewed for WLKY News
Perlara Drug Repurposing screen update
Cure DHDDS Virtual Conference: Summary Report
Mel Dixon to speak at Festival of Genomics in 2024
Medical Podcast features DHDDS parents & advocates from Portugal.
First DHDDS Virtual Conference - September 2023
Cure DHDDS features in SW Londoner
Launch of Cure DHDDS USA
We have been working with Zoe and John for some months now developing research opportunities and building on our network of scientific experts. Together we are stronger and can work faster to find a treatment for these ultra rare mutations.
New contract signed for research in Montreal
Perlara drug repurposing contract signed
Cure DHDDS Raise awareness on American TV
Cure DHDDS on ITV London Tonight
Cure DHDDS Patron on Channel 4
Mel Dixon speaks at Beacons Conference 2023
Cure DHDDS Proud to reveal new short film
Produced by: Cine Schools
Biotin as a new therapeutic approach?
Publication: Molecular Genetics and Metabolism
EpiSignature Study into DHDDS Gene Mutation
EpiSignature is a study of genomic DNA methylation patterns (beyond the coding sequences) to differentiate patients with similar or different phenotypes and genetic changes at the DNA coding level.
Genetic changes in the DHDDS gene have been found in some cases to be associated with a progressive course, while in other cases a static course. EpiSignature tries to determine whether there is any significant difference in methylation pattern that could account for such difference, thus potentially providing some insight for progression and prognosis.
Charity founders in South East Genomics article
Cure DHDDS founders Mel and Charlie Dixon feature in South East Genomics article discussing the struggles and opportunities that come with an ultra rare genetic diagnosis.